Publication:
Issues in women's participation in a phase III community HIV vaccine trial in Thailand

dc.contributor.authorJaranit Kaewkungwalen_US
dc.contributor.authorPunnee Pitisuttithumen_US
dc.contributor.authorSupachai Rerks-Ngarmen_US
dc.contributor.authorSorachai Nitayaphanen_US
dc.contributor.authorChirasak Khamboonruangen_US
dc.contributor.authorPrayura Kunasolen_US
dc.contributor.authorPravan Suntharasamaien_US
dc.contributor.authorSwangjai Pungpaken_US
dc.contributor.authorSirivan Vanijanontaen_US
dc.contributor.authorValai Bussaratiden_US
dc.contributor.authorWirach Maek-A-Nantawaten_US
dc.contributor.authorJittima Dhitavaten_US
dc.contributor.authorPrasert Thongcharoenen_US
dc.contributor.authorRungrawee Pawaranaen_US
dc.contributor.authorYupa Sabmeeen_US
dc.contributor.authorMike W. Benensonen_US
dc.contributor.authorPatricia Morganen_US
dc.contributor.authorRobert J. O'Connellen_US
dc.contributor.authorJerome Kimen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherThailand Ministry of Public Healthen_US
dc.contributor.otherArmed Forces Research Institute of Medical Sciences, Thailanden_US
dc.contributor.otherU.S. Military HIV Research Programen_US
dc.date.accessioned2018-10-19T05:00:11Z
dc.date.available2018-10-19T05:00:11Z
dc.date.issued2013-11-04en_US
dc.description.abstractTo assess qualities and outcomes of women participating in a large, community-based HIV vaccine trial, the present study was conducted among female participants of the RV 144 prime-boost trial in Thailand from 2003 to 2009. Qualities of participation refer to complete vaccination, retention, and status change. Outcomes of participation refer to incident rate, adverse event, and participation impact event. A total of 6,334 (38.6%) women participated in the trial, of whom about 50% were classified as low risk and 11% as high risk. About 85% of participants completed four vaccinations and 76% were included in the per-protocol analysis of the on-time vaccination schedule. More women (88%) completed 42 months follow-up compared with men (85%). Women aged 21 and above had more adverse events compared to younger age groups. More women (5%) compared with men (3%) reported participation impact events (PIEs). High-risk women had more PIEs and a higher infection rate compared to the low-risk group. Complete vaccination and retention on last follow-up were more common in married women aged above 21, and being a housewife. Female volunteers showed the same qualities and outcomes of participation as males in the HIV vaccine trial. There was no statistically significant difference in vaccine efficacy between men and women, especially among the high-risk and married women. The study highlighted the important behavioral, social, and cultural issues that could be considered for future HIV vaccine trial designs. © Copyright 2013, Mary Ann Liebert, Inc. 2013.en_US
dc.identifier.citationAIDS Research and Human Retroviruses. Vol.29, No.11 (2013), 1524-1534en_US
dc.identifier.doi10.1089/aid.2012.0265en_US
dc.identifier.issn19318405en_US
dc.identifier.issn08892229en_US
dc.identifier.other2-s2.0-84886689572en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/31840
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84886689572&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleIssues in women's participation in a phase III community HIV vaccine trial in Thailanden_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84886689572&origin=inwarden_US

Files

Collections